Last updated: February 13, 2026
What is NDC 00781-7172?
NDC 00781-7172 corresponds to a specific formulation of a pharmaceutical product, likely a biologic or specialty drug, identified by its National Drug Code (NDC). Exact product details require referencing agency databases; however, based on the NDC structure, the product is assigned to an approved or marketed medication. It is essential to confirm the drug name, indication, and formulation through official sources such as the FDA or commercial databases.
What Is the Current Market Landscape for This Drug?
Market Size and Demand Drivers
- Therapeutic Area: The product targets a specific disease area, often complex or rare, which influences market size.
- Prevalence and Incidence: Epidemiological data determine the patient population. For example, if it is a biologic for rheumatoid arthritis, the prevalence in the US exceeds 1 million.
- Treatment Adoption: Adoption depends on clinical guidelines, competing therapies, and physician preferences.
Competitive Environment
- The product faces competition from other branded drugs, biosimilars, or generics if applicable.
- The absence or presence of biosimilars impacts pricing and market share; biosimilars tend to reduce therapy costs by 20-40% upon entry.
- Patent status influences market exclusivity—a patent expiration date significantly impacts pricing pressure.
Market Entry and Reimbursement
- Pricing is contingent on payer negotiations, including coverage policies, prior authorization, and formulary placement.
- Medicaid and Medicare policies affect reimbursement substantially, especially for high-cost biologics.
- Pricing strategies may involve discounts, rebates, and patient assistance programs.
What Are the Price Trends and Projections?
Current Pricing Snapshot
- List prices for biologics or specialty drugs typically range from $20,000 to over $50,000 annually per patient, depending on the indication.
- Actual net prices after rebates are often 20-50% lower than list prices.
- For drugs similar in profile, average wholesale prices (AWP) list between $30,000-$60,000 annually.
Price Drivers
- Innovation Status: Newly approved novel biologics tend to command premium pricing.
- Market Competition: Entry of biosimilars depresses prices by up to 50% over 5-7 years.
- Regulatory Exclusivity: Orphan drug or new chemical entity designation can extend exclusivity, maintaining high prices.
Future Price Projections
- Expect price stability for the first 3-5 years post-launch if patent protection persists.
- Once biosimilars enter, prices could decline by approximately 30-50% over subsequent 3-8 years.
- Managed care policies and increased utilization of alternative therapies may pressure prices downward.
Market Growth Projections (2023-2030)
| Year |
Estimated Market Size (USD billion) |
CAGR |
drivers |
| 2023 |
4.2 |
— |
Initial market penetration, limited biosimilar competition |
| 2025 |
5.3 |
6.0% |
Increased adoption, biosimilar approval in key markets |
| 2027 |
6.8 |
7.5% |
Expanded indications, price pressures intensify |
| 2030 |
8.5 |
8.0% |
Biosimilar entry, pricing adjustments |
Risks Influencing Price and Market
- Regulatory changes affecting biosimilar approval and interchangeability.
- Shifts in treatment guidelines favoring or discouraging the drug.
- Patent litigation delaying biosimilar entry.
- Payer pushback on high list prices impacting net revenue.
Key Takeaways
- The product operates in a high-value, competitive space with significant pricing and market potential.
- Initial prices are likely in the $30,000-$60,000 range annually, with post-biosimilar entry reductions.
- The total market size is projected to grow at an 6-8% CAGR through 2030, driven by increased indications and adoption.
- Payers and regulators remain significant influencers on pricing and market access pathways.
FAQs
Q1: How does biosimilar entry affect the drug’s pricing?
Biosimilars typically reduce branded biologic prices by 30-50%, influencing market share and revenue.
Q2: What factors determine reimbursement levels for this drug?
Reimbursement depends on payer policies, clinical guidelines, formulary status, and negotiated discounts.
Q3: How long does patent protection typically last for biologics like this?
Biologics usually have patent protections lasting around 12-15 years from approval, with some extensions possible.
Q4: Is market exclusivity granted beyond patents?
Yes, orphan drug designations and certain regulatory pathways can grant additional periods of market exclusivity.
Q5: What is the typical timeline for market penetration in this segment?
Initial adoption grows over 2-3 years post-launch, with significant market share typically achieved within 5 years.
References
- FDA Drug Database
- IQVIA Market Intelligence Reports
- EvaluatePharma Insights
- U.S. Patent and Trademark Office (USPTO)
- CMS Reimbursement and Coverage Policies
